Randomized, placebo controlled Phase III study
of antibody to endotoxin
–Intervention:
Single administration
–Endpoint:
Difference in 28 day mortality rates
•Placebo
arm: estimate 30% mortality
•Treatment
arm: hope for 23% mortality
–Analysis:
Large sample test of binomial proportions
•Frequentist
based inference
•Type
I error: one-sided 0.025
•Power:
90% to detect θ < -0.07
•Point
estimate with low bias, MSE; 95% CI
•